Replicate Bioscience
Developer of self-replicating RNA (srRNA) therapeutics. The company designs and engineers srRNA vectors and maintains a customizable library of synthetic srRNA constructs, advancing a pipeline of preclinical and early clinical candidates across infectious disease, oncology, and autoimmune/inflammatory indications. Founded in 2014, the organization has pursued technology licensing from academic institutions and engages scientific advisory and clinical leadership to support translation toward clinical studies.
Industries
Nr. of Employees
small (1-50)
Replicate Bioscience
San Diego, California, United States
Patents
Compositions and methods for the prevention and treatment of rabies virus infection
US-11730804-B1
View DetailsCompositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
US-11510975-B1
View Details
Compositions and methods for the prevention and treatment of rabies virus infection
US-11730804-B1
View DetailsCompositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
US-11510975-B1
View DetailsProducts
srRNA therapeutic pipeline
A pipeline of self-replicating RNA therapeutic candidates under development for infectious diseases, oncology, and autoimmune/inflammatory disorders.
RBI-1000
Precision immunotherapy candidate for ER+ breast cancer addressing endocrine therapy resistance.
RBI-4000
Rabies vaccine utilizing srRNA technology with a viral glycoprotein mechanism of action, currently in Phase 1 complete stage.
RBI-5000
Infectious mononucleosis vaccine candidate targeting multiple antigens of Epstein Barr virus.
RBI-6000
RSV/hMPV/PIV vaccine candidate using multiple antigens.
RBI-X000
Cardiometabolic therapeutic candidate for obesity, diabetes, and other conditions.
srRNA therapeutic pipeline
A pipeline of self-replicating RNA therapeutic candidates under development for infectious diseases, oncology, and autoimmune/inflammatory disorders.
RBI-1000
Precision immunotherapy candidate for ER+ breast cancer addressing endocrine therapy resistance.
RBI-4000
Rabies vaccine utilizing srRNA technology with a viral glycoprotein mechanism of action, currently in Phase 1 complete stage.
RBI-5000
Infectious mononucleosis vaccine candidate targeting multiple antigens of Epstein Barr virus.
RBI-6000
RSV/hMPV/PIV vaccine candidate using multiple antigens.
RBI-X000
Cardiometabolic therapeutic candidate for obesity, diabetes, and other conditions.
Expertise Areas
- Self-replicating RNA therapeutics
- srRNA vaccine development
- Oncology immunotherapy
- Preclinical candidate discovery and optimization
Key Technologies
- Self-replicating RNA (srRNA) vectors
- Synthetic RNA vector libraries
- srRNA vaccine platforms
- Imaging technologies for RNA regulation
News & Updates
News article profiling the company's focus on self-replicating RNA and potential advantages over linear mRNA approaches.
Press release announcing a grant award to support development of srRNA vaccine candidates for tuberculosis.
Press release announcing clinical and board appointments to support clinical and development activities.
News article profiling the company's focus on self-replicating RNA and potential advantages over linear mRNA approaches.
Press release announcing a grant award to support development of srRNA vaccine candidates for tuberculosis.
Press release announcing clinical and board appointments to support clinical and development activities.